ITI Pharma and Healthcare Fund Direct Growth
EquitySector - HealthcareVery High Risk
Direct
NAV (20-Dec-24)
Returns (Since Inception)
Fund Overview
Fund Size
₹218 Cr
Expense Ratio
0.47%
ISIN
INF00XX01BO9
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
11 Nov 2021
About this fund
As of 20-Dec-24, it has a Net Asset Value (NAV) of ₹18.17, Assets Under Management (AUM) of 217.92 Crores, and an expense ratio of 0.47%.
- ITI Pharma and Healthcare Fund Direct Growth has given a CAGR return of 21.17% since inception.
- The fund's asset allocation comprises around 95.26% in equities, 0.00% in debts, and 4.74% in cash & cash equivalents.
- You can start investing in ITI Pharma and Healthcare Fund Direct Growth with a SIP of ₹1000 or a Lumpsum investment of ₹5000.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+47.69%
+43.28% (Cat Avg.)
3 Years
+23.42%
+21.60% (Cat Avg.)
Since Inception
+21.17%
— (Cat Avg.)
Portfolio Summaryas of 30th November 2024
| Equity | ₹207.59 Cr | 95.26% |
| Others | ₹10.33 Cr | 4.74% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹33.18 Cr | 15.23% |
| Lupin Ltd | Equity | ₹13.11 Cr | 6.02% |
| Suven Pharmaceuticals Ltd | Equity | ₹12.55 Cr | 5.76% |
| Aurobindo Pharma Ltd | Equity | ₹10.57 Cr | 4.85% |
| Divi's Laboratories Ltd | Equity | ₹10.4 Cr | 4.77% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹10.36 Cr | 4.75% |
| Torrent Pharmaceuticals Ltd | Equity | ₹8.05 Cr | 3.70% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹7.7 Cr | 3.53% |
| Laurus Labs Ltd | Equity | ₹6.98 Cr | 3.20% |
| Syngene International Ltd | Equity | ₹5.9 Cr | 2.71% |
| Dr Reddy's Laboratories Ltd | Equity | ₹5.87 Cr | 2.69% |
| Alkem Laboratories Ltd | Equity | ₹5.5 Cr | 2.52% |
| Treps 02-Dec-2024 | Cash - Repurchase Agreement | ₹5.42 Cr | 2.49% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹5.37 Cr | 2.47% |
| Net Receivables / (Payables) | Cash | ₹4.91 Cr | 2.25% |
| Orchid Pharma Ltd | Equity | ₹4.72 Cr | 2.16% |
| Piramal Pharma Ltd | Equity | ₹4.45 Cr | 2.04% |
| Strides Pharma Science Ltd | Equity | ₹4.39 Cr | 2.01% |
| HealthCare Global Enterprises Ltd | Equity | ₹4 Cr | 1.84% |
| Mankind Pharma Ltd | Equity | ₹3.9 Cr | 1.79% |
| Shilpa Medicare Ltd | Equity | ₹3.66 Cr | 1.68% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹3.51 Cr | 1.61% |
| FDC Ltd | Equity | ₹3.29 Cr | 1.51% |
| Ajanta Pharma Ltd | Equity | ₹3.29 Cr | 1.51% |
| Wockhardt Ltd | Equity | ₹3.29 Cr | 1.51% |
| Neuland Laboratories Limited | Equity | ₹3.27 Cr | 1.50% |
| Caplin Point Laboratories Ltd | Equity | ₹3.24 Cr | 1.49% |
| Supriya Lifescience Ltd | Equity | ₹3.11 Cr | 1.43% |
| Ipca Laboratories Ltd | Equity | ₹3.03 Cr | 1.39% |
| HDFC Life Insurance Co Ltd | Equity | ₹3.03 Cr | 1.39% |
| Fortis Healthcare Ltd | Equity | ₹2.96 Cr | 1.36% |
| Gland Pharma Ltd | Equity | ₹2.64 Cr | 1.21% |
| Emcure Pharmaceuticals Ltd | Equity | ₹2.61 Cr | 1.20% |
| Rainbow Childrens Medicare Ltd | Equity | ₹2.56 Cr | 1.17% |
| Sumitomo Chemical India Ltd Ordinary Shares | Equity | ₹2.49 Cr | 1.14% |
| Cipla Ltd | Equity | ₹2.37 Cr | 1.09% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹2.25 Cr | 1.03% |
Allocation By Market Cap (Equity)
Large Cap Stocks
35.40%
Mid Cap Stocks
26.13%
Small Cap Stocks
31.03%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹198.79 Cr | 91.22% |
| Financial Services | ₹3.03 Cr | 1.39% |
| Basic Materials | ₹2.49 Cr | 1.14% |
Risk & Performance Ratios
Standard Deviation
This fund
15.08%
Cat. avg.
15.68%
Lower the better
Sharpe Ratio
This fund
1.04
Cat. avg.
0.87
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.61
Higher the better
Fund Managers
Dhimant Shah
Since December 2022
Rohan Korde
Since November 2021
Additional Scheme Detailsas of 30th November 2024
ISIN INF00XX01BO9 | Expense Ratio 0.47% | Exit Load 1.00% | Fund Size ₹218 Cr | Age 3 years 1 month | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark Nifty Healthcare TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
Dividend Taxation:
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Sector - Healthcare Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹32.33 Cr | 47.0% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 0.9% | 1.0% | ₹854.32 Cr | 39.5% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹854.32 Cr | 37.6% |
| Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹42.05 Cr | 43.4% |
| ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹217.92 Cr | 47.7% |
| ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹217.92 Cr | 44.9% |
| Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2742.91 Cr | 43.0% |
| Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2742.91 Cr | 40.9% |
| Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹840.57 Cr | 40.1% |
| Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹19.39 Cr | 42.4% |
About the AMC
Other Funds by ITI Mutual Fund
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
|---|---|---|---|---|
| ITI Focused Equity Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹508.96 Cr | 29.8% |
| ITI Liquid Fund Direct Growth Low to Moderate Risk | 0.1% | 0.0% | ₹51.88 Cr | 7.1% |
| ITI Ultra Short Duration Fund Direct Growth Low to Moderate Risk | 0.1% | 0.0% | ₹216.46 Cr | 7.5% |
| ITI Multi Cap Fund Direct Growth Very High Risk | 0.3% | 1.0% | ₹1381.80 Cr | 26.9% |
| ITI Value Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹311.43 Cr | 25.3% |
| ITI Conservative Hybrid Fund Direct Growth Moderate Risk | 0.2% | 0.0% | ₹14.80 Cr | 8.9% |
| ITI Dynamic Bond Fund Direct Growth Moderate Risk | 0.1% | 0.0% | ₹53.13 Cr | 9.4% |
| ITI Balanced Advantage Fund Direct Growth Moderately High risk | 0.6% | 1.0% | ₹388.43 Cr | 17.3% |
| ITI Small Cap Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹2438.95 Cr | 42.1% |
| ITI Large Cap Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹376.92 Cr | 20.3% |
| ITI Banking & PSU Debt Fund Direct Growth Low to Moderate Risk | 0.1% | 0.0% | ₹30.02 Cr | 8.1% |
| ITI Banking and Financial Services Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹271.75 Cr | 10.5% |
| ITI Arbitrage Fund Direct Growth Low Risk | 0.2% | 0.0% | ₹37.55 Cr | 8.1% |
| ITI Overnight Fund Direct Growth Low Risk | 0.1% | 0.0% | ₹16.51 Cr | 6.5% |
| ITI Mid Cap Fund Direct Growth Very High Risk | 0.3% | 1.0% | ₹1133.44 Cr | 37.7% |
| ITI Long Term Equity Fund Direct Growth Very High Risk | 0.5% | 0.0% | ₹398.64 Cr | 28.4% |
| ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹217.92 Cr | 47.7% |
| ITI Flexi Cap Fund Direct Growth Very High Risk | 0.3% | 1.0% | ₹1287.64 Cr | 32.2% |
Risk Level
Your principal amount will be at Very High Risk
Unlock Expert Insights!
Related Articles
Still got questions?
We're here to help.
What is the current NAV of ITI Pharma and Healthcare Fund Direct Growth?
What are the returns of ITI Pharma and Healthcare Fund Direct Growth?
What is the portfolio composition of ITI Pharma and Healthcare Fund Direct Growth?
Who manages the ITI Pharma and Healthcare Fund Direct Growth?
- Dhimant Shah
- Rohan Korde
Trending Mutual Funds Searches
Popular Equity Funds
Popular Debt Funds
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.